The Library

A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis

Tools

Carson, Connor, Antoniou, Maria, Begoña Ruiz-Argüello, Maria, Alcami, Antonio, Christodoulou, Vasiliki , Messaritakis, Ippokratis, Blackwell, Jenefer M. and Courtenay, Orin. (2008) A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine, Vol.27 (No.7). pp. 1080-1086. ISSN 0264-410X

Preview

PDF
WRAP_courtenay_Carson_et_al__DNA_MVA_MS_final_word_doc.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (231Kb)

Official URL: http://dx.doi.org/10.1016/j.vaccine.2008.11.094 ...

Abstract

Previous studies demonstrated safety, immunogenicity and efficacy of DNA/modified vaccinia virus Ankara (MVA) prime/boost vaccines expressing tryparedoxin peroxidase (TRYP) and Leishmania homologue of the mammalian receptor for activated C kinase (LACK) against Leishmania major challenge in mice, which was consistent with results from TRYP protein/adjuvant combinations in non-human primates. This study aimed to conduct safety and immunogenicity trials of these DNA/MVA vaccines in dogs, the natural reservoir host of Leishmania infantum, followed-up for 4 months post-vaccination. In a cohort of 22 uninfected outbred dogs, blinded randomised administration of 1000 μg (high dose) or 100 μg (low dose) DNA prime (day 0) and 1 × 108 pfu MVA boost (day 28) was shown to be safe and showed no clinical side effects. High dose DNA/MVA vaccinated TRYP dogs produced statistically higher mean levels of the type-1 pro-inflammatory cytokine IFN-γ than controls in whole blood assays (WBA) stimulated with the recombinant vaccine antigen TRYP, up to the final sampling at day 126, and in the absence of challenge with Leishmania. TRYP vaccinated dogs also demonstrated significantly higher TRYP-specific total IgG and IgG2 subtype titres than in controls, and positive in vivo intradermal reactions at day 156 in the absence of natural infection, observed in 6/8 TRYP vaccinated dogs. No significant increases in IFN-γ in LACK-stimulated WBA, or in LACK-specific IgG levels, were detected in LACK vaccinated dogs compared to controls, and only 2/9 LACK vaccinated dogs demonstrated DTH responses at day 156. In all groups, IgG1 subclass responses and antigen-specific stimulation of IL-10 were similar to controls demonstrating an absence of Th2/Treg response, as expected in the absence of in vivo restimulation or natural/experimental challenge with Leishmania. These collective results indicate significant antigen-specific type-1 responses and in vivo memory phase cellular immune responses, consistent with superior potential for protective vaccine immunogenicity of DNA/MVA TRYP over LACK.

Item Type:	Journal Article
Subjects:	Q Science > QR Microbiology > QR355 Virology Q Science > QH Natural history > QH426 Genetics
Divisions:	Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH):	Leishmaiasis, Dogs -- Diseases, DNA vaccines, Immunogenetics
Journal or Publication Title:	Vaccine
Publisher:	Elsevier Ltd.
ISSN:	0264-410X
Date:	16 December 2008
Volume:	Vol.27
Number:	No.7
Page Range:	pp. 1080-1086
Identification Number:	10.1016/j.vaccine.2008.11.094
Status:	Peer Reviewed
Access rights to Published version:	Open Access
Funder:	Biotechnology and Biological Sciences Research Council (Great Britain) (BBSRC), Wellcome Trust (London, England), European Union (EU)
References:	[1] Mauricio IL, Stothard JR, Miles MA. The strange case of Leishmania chagasi. Parasitol Today 2000;16(5):188-89. [2] WHO/TDR. http://www.who.int/tdr/diseases/leish/direction.htm, 2002. [3] Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996;55(2):125-30. [4] Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectiousness in a cohort of Brazilian dogs: Why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002;186(9):1314-20. [5] Dantas-Torres F. Leishmune® vaccine: The newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 2006;141(1-2):1-8. [6] Borja-Cabrera GP, Pontes NNC, da Silva VO, de Souza EP, Santos WR, Gomes EM, et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 2002;20(27-28):3277-84. [7] Parra LE, Borja-Cabrera GP, Santos FN, Souza LOP, Palatnik-de-Sousa CB, Menz I. Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 2007;25(12):2180-86. [8] Mendez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YAW, et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 2001;166(8):5122-28. [9] Dumonteil E. DNA vaccines against protozoan parasites: Advances and challenges. J Biomed Biotechnol 2007;Article 90520. [10] Levick MP, Blackwell JM, Connor V, Coulson RMR, Miles A, Smith HE, et al. An expressed sequence tag analysis of a full-length, spliced-leader cDNA library from Leishmania major promastigotes. Mol Biochem Parasit 1996;76(1-2):345-48. [11] Levick MP, Tetaud E, Fairlamb AH, Blackwell JM. Identification and characterisation of a functional peroxidoxin from Leishmania major. Mol Biochem Parasit 1998;96(1-2):125-37. [12] Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66(7):3279-89. [13] Almeida R, Norrish A, Levick M, Vetrie D, Freeman T, Vilo J, et al. From genomes to vaccines: Leishmania as a model. Philos T Roy Soc B 2002;357(1417):5-11. [14] Stober CB, Lange UG, Roberts MTM, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 2005;175(4):2517-24. [15] Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Skeiky YAW, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001;69(6):4103-08. [16] Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006;24(21):4554-61. [17] Stober CB, Lange UG, Roberts MTM, Alcami A, Blackwell JM. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice. Infect Immun 2007;75(2):852-60. [18] Jacob J, Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 1999;399(6736):593-7. [19] Mougneau E, Altare F, Wakil AE, Zheng SC, Coppola T, Wang ZE, et al. Expression cloning of a protective Leishmania antigen. Science 1995;268(5210):563-66. [20] Ramiro MJ, Zarate JJ, Hanke T, Rodriguez D, Rodriguez JR, Esteban M, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003;21(19-20):2474-84. [21] Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008;26(3):333-44. [22] Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4(4):397-402. [23] Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978;41:225-34. [24] Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immun 2005;54(5):453-67. [25] Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002;20(15):1949-55. [26] Moorthy VS, Pinder M, Reece WHH, Watkins K, Atabani S, Hannan C, et al. Safety and Immunogenicity of DNA/Modified Vaccinia Virus Ankara Malaria Vaccination in African Adults. J Infect Dis 2003;188(8):1239-44. [27] McShane H, Brookes R, Gilbert SC, Hill AVS. Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001;69(2):681-86. [28] Palmowski MJ, Choi EML, Hermans IF, Gilbert SC, Chen JL, Gileadi U, et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002;168(9):4391-98. [29] Gradoni L, Gramiccia M. Leishmaniosis. In: OIE manual of standards for diagnostic tests and vaccines for terrestrial animals. 4th ed. Paris, France, Office International des Epizooties, 2004: 803-12. [30] Quinnell RJ, Courtenay O, Garcez L, Dye C. The epidemiology of canine leishmaniasis: Transmission rates estimated from a cohort study in Amazonian Brazil. Parasitology 1997;115(2):143-56. [31] Parvizi P, Mauricio I, Aransay AM, Miles MA, Ready PD. First detection of Leishmania major in peridomestic Phlebotomus papatasi from Isfahan province, Iran: Comparison of nested PCR of nuclear ITS ribosomal DNA and semi-nested PCR of minicircle kinetoplast DNA. Acta Trop 2005;93(1):75-83. [32] UK Home Office. Code of practice for the housing and care of animals used in scientific procedures (1989). http://scienceandresearch.homeoffice.gov.uk/animal-research. [33] Alexander B. Sampling methods for phlebotomine sandflies. Med Vet Entomol 2000;14(2):109-22. [34] European Medicines Agency: Evaluation of the safety of veterinary medicinal products for the target animals. 7AE2a 1994;Vol 7. [35] Shifrine M, Taylor NJ, Rosenblatt LS, Wilson FD. Comparison of whole-blood and purified canine lymphocytes in a lymphocyte-stimulation microassay. Am J Vet Res 1978;39(4):687-90. [36] Tijssen P. Practice and theory of enzyme immunoassays. 1st ed. Amsterdam Elsevier Science Publishers B.V., 1985. [37] Pinelli E, Killick-kendrick R, Wagenaar J, Bernadina W, Delreal G, Ruitenberg J. Cellular and humoral immune-responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 1994;62(1):229-35. [38] Mackett M, Smith GL, Moss B. The construction and characterization of vaccinia virus recombinants expressing foreign genes. In: Glover DM, editor. DNA Cloning: A Practical Approach. IRL Oxford, 1985: 191-211. [39] European Medicines Agency: Specific requirements for the production and control of live and inactivated viral and bacterial vaccines for cats and dogs 7BIm13a 1995;Vol 7. [40] European Commission: Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes (1986). http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm. [41] Kaye PM, Curry AJ, Blackwell JM. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 1991;146(8):2763-70. [42] Ferreira JHL, Gentil LG, Dias SS, Fedeli CEC, Katz S, Barbieri CL. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Vaccine 2008;26(5):677-85. [43] Wilson ME, Jeronimo SMB, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathogenesis 2005;38(4):147-60. [44] Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005;23(22):2825-40. [45] Pinelli E, Gonzalo RM, Boog CJP, Rutten V, Gebhard D, Delreal G, et al. Leishmania infantum-specific T-Cell lines derived from asymptomatic dogs that lyse infected macrophages in a Major Histocompatibility Complex-restricted manner. Eur J Immunol 1995;25(6):1594-600. [46] Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi F, Eravani D, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005;23(28):3716-25. [47] Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial. Vaccine 2007;25(21):4223-34. [48] Fujiwara RT, Vale AM, Franca Da Silva JC, Da Costa RT, Quetz JDS, Martins Filho OA, et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 2005;36(5-6):827-38. [49] Day MJ. Immunoglobulin G subclass distribution in canine leishmaniosis: A review and analysis of pitfalls in interpretation. Veterinary Parasitol 2007;147(1-2):2-8. [50] Reed SG, Scott P. T-Cell and Cytokine Responses in Leishmaniasis. Curr Opin Immunol 1993;5(4):524-31. [51] Reiner SL, Locksley RM. Lessons from Leishmania - a Model for Investigations of Cd4+ Subset Differentiation. Infect Agent Dis 1992;1(1):33-42. [52] Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17(3):138-46. [53] Barbieri CL. Immunology of canine leishmaniasis. Parasite Immunol 2006;28(7):329-37. [54] Pinheiro PHD, Dias SD, Eulalio KD, Mendonca IL, Katz S, Barbieri CC. Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses. Infect Immun 2005;73(6):3787-89. [55] Chamizo C, Moreno J, Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunop 2005;103(1-2):67-75. [56] Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romao P, Silveira H. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunop 2002;88(1-2):21-30. [57] Quinnell RJ, Courtenay O, Shaw MA, Day MJ, Garcez LM, Dye C, et al. Tissue cytokine responses in canine visceral leishmaniasis. J Infect Dis 2001;183(9):1421-24. [58] Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007;25(42):7450-58. [59] Moreno J, Nieto J, Masina S, Canavate C, Cruz I, Chicharro C, et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 2007;25(29):5290-300.
URI:	http://wrap.warwick.ac.uk/id/eprint/447